Search research articles
Contact Us
Filters
Showing results (11-20 of 40) with videos related to
Page
of 4
Sort By:
Clinical and Experimental Rheumatology
|
October 17, 2015
Limitations of clinical trials in chronic diseases: is the efficacy of methotrexate (MTX) underestimated in polyarticular psoriatic arthritis on the basis of limitations of clinical trials more than on limitations of MTX, as was seen in rheumatoid arthritis?
Theodore Pincus, Martin J Bergman, Yusuf Yazici
The Journal of Rheumatology
|
October 16, 2021
Should Quantitative Measures and Management of Rheumatoid Arthritis Include More Than Control of Inflammatory Activity?
Theodore Pincus, Martin J Bergman, Yusuf Yazici
Arthritis & Rheumatology (Hoboken, N.J.)
|
March 1, 2021
Use of Precision Medicine to Guide Treatment of Patients With Rheumatoid Arthritis: Comment on the Article by Tao et al
Stanley B Cohen, Theodore Mellors, Martin J Bergman
Rheumatic Diseases Clinics of North America
|
December 8, 2009
How to collect an MDHAQ to provide rheumatology vital signs (function, pain, global status, and RAPID3 scores) in the infrastructure of rheumatology care, including some misconceptions regarding the MDHAQ
Theodore Pincus, Alyce M Oliver, Martin J Bergman
Rheumatic Diseases Clinics of North America
|
December 8, 2009
Complex measures and indices for clinical research compared with simple patient questionnaires to assess function, pain, and global estimates as rheumatology "vital signs" for usual clinical care
Theodore Pincus, Martin J Bergman, Ross Maclean, et al.
Clinical and Experimental Rheumatology
|
October 18, 2012
Treat-to-target: not as simple as it appears
Theodore Pincus, Isabel Castrejón, Martin J Bergman, et al.
Plos One
|
June 10, 2016
Three-Quarters of Persons in the US Population Reporting a Clinical Diagnosis of Fibromyalgia Do Not Satisfy Fibromyalgia Criteria: The 2012 National Health Interview Survey
Brian Walitt, Robert S Katz, Martin J Bergman, et al.
Rheumatology (Oxford, England)
|
December 11, 2019
Disease activity measures at baseline predict structural damage progression: data from the randomized, controlled AMPLE and AVERT trials
Edward C Keystone, Harris A Ahmad, Yusuf Yazici, et al.
Autoimmune Diseases
|
December 26, 2013
Composite Indices Using 3 or 4 Components of the Core Data Set Have Similar Predictive Ability to Measure Disease Activity in RA: Evidence from the DANCER and REFLEX Studies
Martin J Bergman, William Reiss, Carol Chung, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
December 20, 2016
Limited Value of the Multi-Biomarker Disease Activity Assay Compared to the Routine Assessment of Patient Index Data 3 (RAPID3) Score in the Prognosis of Important Clinical Outcomes in Rheumatoid Arthritis: Comment on the Article by Fleischmann et al and Accompanying Editorial by Davis
Theodore Pincus, Joel A Block, Yusuf Yazici, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 40) with videos related to
Sort By:
Page
of 4
Clinical and Experimental Rheumatology
|
October 17, 2015
Limitations of clinical trials in chronic diseases: is the efficacy of methotrexate (MTX) underestimated in polyarticular psoriatic arthritis on the basis of limitations of clinical trials more than on limitations of MTX, as was seen in rheumatoid arthritis?
Theodore Pincus, Martin J Bergman, Yusuf Yazici
The Journal of Rheumatology
|
October 16, 2021
Should Quantitative Measures and Management of Rheumatoid Arthritis Include More Than Control of Inflammatory Activity?
Theodore Pincus, Martin J Bergman, Yusuf Yazici
Arthritis & Rheumatology (Hoboken, N.J.)
|
March 1, 2021
Use of Precision Medicine to Guide Treatment of Patients With Rheumatoid Arthritis: Comment on the Article by Tao et al
Stanley B Cohen, Theodore Mellors, Martin J Bergman
Rheumatic Diseases Clinics of North America
|
December 8, 2009
How to collect an MDHAQ to provide rheumatology vital signs (function, pain, global status, and RAPID3 scores) in the infrastructure of rheumatology care, including some misconceptions regarding the MDHAQ
Theodore Pincus, Alyce M Oliver, Martin J Bergman
Rheumatic Diseases Clinics of North America
|
December 8, 2009
Complex measures and indices for clinical research compared with simple patient questionnaires to assess function, pain, and global estimates as rheumatology "vital signs" for usual clinical care
Theodore Pincus, Martin J Bergman, Ross Maclean, et al.
Clinical and Experimental Rheumatology
|
October 18, 2012
Treat-to-target: not as simple as it appears
Theodore Pincus, Isabel Castrejón, Martin J Bergman, et al.
Plos One
|
June 10, 2016
Three-Quarters of Persons in the US Population Reporting a Clinical Diagnosis of Fibromyalgia Do Not Satisfy Fibromyalgia Criteria: The 2012 National Health Interview Survey
Brian Walitt, Robert S Katz, Martin J Bergman, et al.
Rheumatology (Oxford, England)
|
December 11, 2019
Disease activity measures at baseline predict structural damage progression: data from the randomized, controlled AMPLE and AVERT trials
Edward C Keystone, Harris A Ahmad, Yusuf Yazici, et al.
Autoimmune Diseases
|
December 26, 2013
Composite Indices Using 3 or 4 Components of the Core Data Set Have Similar Predictive Ability to Measure Disease Activity in RA: Evidence from the DANCER and REFLEX Studies
Martin J Bergman, William Reiss, Carol Chung, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
December 20, 2016
Limited Value of the Multi-Biomarker Disease Activity Assay Compared to the Routine Assessment of Patient Index Data 3 (RAPID3) Score in the Prognosis of Important Clinical Outcomes in Rheumatoid Arthritis: Comment on the Article by Fleischmann et al and Accompanying Editorial by Davis
Theodore Pincus, Joel A Block, Yusuf Yazici, et al.
Page
of 4